Ustekinumab exerts its therapeutic effects by targeting the p40 subunit, which is shared by both interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines involved in inflammatory processes and in the activation of natural killer (NK) cells and CD4+ T lymphocytes in psoriasis. This evidence concerns the gene IL23A and psoriasis.